HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Lineage Cell Therapeutics (AMEX:LCTX) and maintained a $7 price target.
August 11, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lineage Cell Therapeutics (AMEX:LCTX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $7.
The reiteration of a 'Buy' rating and maintenance of a $7 price target by HC Wainwright & Co. indicates a positive outlook for Lineage Cell Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100